Moxie

Element 7 Chula Vista Launch a Huge Success as Customers Embrace Element 7's Retail Cannabis Model

Retrieved on: 
Monday, July 11, 2022
Taking Off (film), The Grand Opening, El Viaje Misterioso de Nuestro Jomer (The Mysterious Voyage of Homer), CEO, Industry, Bill shock, Moxie, Music, Central Valley, Nitrogen, Element, State, Golden Joystick Awards, Hotbox, High–low pricing, Drug, Retail, Gelato

CHULA VISTA, Calif., July 11, 2022 /PRNewswire/ -- Element 7 continued to expand its retail footprint across California this week the much-anticipated opening of its newest location in Chula Vista.

Key Points: 
  • CHULA VISTA, Calif., July 11, 2022 /PRNewswire/ -- Element 7 continued to expand its retail footprint across California this week the much-anticipated opening of its newest location in Chula Vista.
  • Element 7's Chula Vista store expands the cannabis company's footprint further into Southern California from its existing 11 cannabis operations in the Central Valley and Northern California.
  • Chula Vista is the nation's 7th fastest growing city which positions Element 7 for tremendous growth in this market.
  • As Robert DiVito, CEO of Element 7 explains, "We're excited to launch Element 7 in Chula Vista, expanding our footprint in California.

Trulieve Celebrates Grand Opening of Medical Dispensary in Coatesville, PA

Retrieved on: 
Thursday, June 2, 2022
CSE, Company, List of monarchs of Prussia, LLC, OTCQX, Cannabis, Growth, Patient, Timeline of cannabis laws in the United States, Moxie, Magnetic deviation, Avenue, Industry, Instagram, Muses, Drug, Facebook

TALLAHASSEE, Fla., June 2, 2022 /PRNewswire/ -- Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the United States, today announced the grand opening of a new Trulieve-branded medical marijuana dispensary under the Permit Harvest of SouthEast PA, LLC. in Coatesville, Penn. Located at 1951 E Lincoln Hwy, Coatesville, PA 19320, the doors will open at 9 a.m. on Thursday June 2, 2022.

Key Points: 
  • TALLAHASSEE, Fla., June 2, 2022 /PRNewswire/ -- Trulieve Cannabis Corp. (CSE: TRUL ) (OTCQX: TCNNF )("Trulieve" or "the Company"), a leading and top-performing cannabis company in the United States, today announced the grand opening of a new Trulieve-branded medical marijuana dispensary under the Permit Harvest of SouthEast PA, LLC.
  • Located at 1951 E Lincoln Hwy, Coatesville, PA 19320, the doors will open at 9 a.m. on Thursday June 2, 2022.
  • To find a location or to learn how to become a registered patient, visit Trulieve.com , follow us on Instagram at trulieve_pa or connect with Trulieve PA on Facebook.
  • Trulieve is listed on the CSE under the symbol TRUL and trades on the OTCQX market under the symbol TCNNF.

Reata Pharmaceuticals Announces FDA Filing Acceptance and Priority Review Designation for the NDA for Omaveloxolone for the Treatment of Patients with Friedreich’s Ataxia

Retrieved on: 
Thursday, May 26, 2022
Health, FDA, Genetics, Other Science, Science, Pharmaceutical, Biotechnology, Diabetes, Inflammation, ATP, Cardiomyopathy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, U.S. Securities and Exchange Commission, European Commission, Nasdaq, Ataxia, New Drug Application, Patient, Priority review, File, Hearing loss, Reata Pharmaceuticals, Extension, Orphan drug, FDA, Research, Omaveloxolone, Literature, Time, Medication, Forward-looking statement, Safety, Muscle weakness, NDA, Therapy, Moxie, Part Two, Oxidative stress, Diagnosis, Visual impairment, Fatigue, Annual report, Pharmaceutical industry, NFE2L2

The FDA grants Priority Review to medicines that may offer significant improvements in the treatment, diagnosis, or prevention of a serious condition.

Key Points: 
  • The FDA grants Priority Review to medicines that may offer significant improvements in the treatment, diagnosis, or prevention of a serious condition.
  • This Designation shortens the FDAs review of the NDA to eight months from the time of submission, versus a standard review timeline of 12 months.
  • The FDA has granted Orphan Drug, Fast Track, and Rare Pediatric Disease Designations to omaveloxolone for the treatment of Friedreichs ataxia.
  • The European Commission has granted Orphan Drug Designation in Europe to omaveloxolone for the treatment of Friedreichs ataxia.

CROOKED MEDIA ANNOUNCES NEW LINEUP FEATURING ORIGINAL CONTENT, COLLABORATIONS + EXCITING, NEW VOICES ALONGSIDE FAN-FAVORITES -- FOR ITS MOST AMBITIOUS SLATE TO DATE SPANNING CULTURE, POLITICS + FOREIGN AFFAIRS

Retrieved on: 
Monday, May 23, 2022
Hook-up, Politics, History, Bell, Social media, Contemporary art, Dear Mama, World, Blazer, Crooked Media, Amazon Music, LOS, News, Policy, Peabody Award, Dread Central, FIFA World Cup, Pod Save the World, Critic's Choice, Culture, Partnership, Man, Podcasts (software), World cup, Pretty Boy, Atmosphere, FIFA, Stitcher Radio, EVP, Season, Wilderness, Democracy, POD, Mental health, Friends, Acquisition, Political lists, The Wilderness, Rubicon, Democratic Party, Television, Video game, Public relations, Entertainment, Moxie, Crooked, Spotify

LOS ANGELES, May 23, 2022 /PRNewswire/ -- Crooked Media, a progressive independent media company that delivers bold content to entertain, inform and inspire action, announces its newest development slate, with podcasts spanning culture, politics and foreign affairs. The 2022 slate includes three original premieres, a new acquisition, new seasons of award-winning favorites and a spinoff series in partnership with hit Men In Blazers Show, with more to be announced.

Key Points: 
  • Crooked Media has launched more than 30 podcasts and digital series since its founding in 2017.
  • The current lineup of ambitious storytelling and analysis generates more than 21 million monthly downloads and consistently ranks at the top of competitive podcast charts.
  • Crooked has received over 50 awards and nominations since 2018, including a prestigious Peabody Award nomination.
  • The show is the latest podcast acquisition for Crooked Media, and will return with new episodes this July.

Reata Pharmaceuticals, Inc. Announces First Quarter 2022 Financial Results and Provides an Update on Clinical Development Programs

Retrieved on: 
Tuesday, May 10, 2022
Health, Other Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Extension, EGFR, Forward-looking statement, Week, Division, GAAP, Moxie, EMA, Nasdaq, U.S. Securities and Exchange Commission, European Medicines Agency, Oxidative stress, Company, NDA, Food, Safety, Glomerular filtration rate, NFE2L2, Patient, Review, Part Two, FDA, Inflammation, Annual report, Therapy, Regulation of tobacco by the U.S. Food and Drug Administration, Ataxia, Marketing, Forecasting, Sale, Medication, Reata Pharmaceuticals, Research, Fine chemical, Pharmaceutical industry, Video game, Reinsurance, Bank, ADPKD

Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (Reata, the Company, our, us, or we), a clinical-stage biopharmaceutical company, today announced financial results for the first quarter of 2022 and provided an update on the Companys business operations and clinical development programs.

Key Points: 
  • Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (Reata, the Company, our, us, or we), a clinical-stage biopharmaceutical company, today announced financial results for the first quarter of 2022 and provided an update on the Companys business operations and clinical development programs.
  • We plan to submit an MAA to the EMA in the fourth quarter of 2022.
  • The Company believes the presentation of these non-GAAP financial measures provides useful information to management and investors regarding the Companys financial condition and results of operations.
  • These non-GAAP financial measures are not intended to be considered in isolation or as a substitute for GAAP financial measures.

Built In Announces the 100 Winners of Its Awards Program Honoring Rising Women in Tech

Retrieved on: 
Wednesday, April 27, 2022
People, News, CEO, Microsoft, CTO, Marketing, Woman, Courage, Equity, Culminating project, Awareness, Strategy, Gender identity, Program, Engineering, Corporate title, DEI, Communication, Demand generation, Loyalty business model, Technology, Moxie, US, Data infrastructure, Sex, IDEA, Purdue University, Hotel manager, Management, Information technology, Moxie's Grill & Bar

CHICAGO, April 27, 2022 /PRNewswire/ -- Built In is pleased to release its 2022 Moxie Awards Program, which honors rising women in tech. See the full winners list below and learn more about the 100 winners here.

Key Points: 
  • CHICAGO, April 27, 2022 /PRNewswire/ -- Built In is pleased to release its 2022 Moxie Awards Program , which honors rising women in tech.
  • Built In 2022 awards program, the Moxies, honors women on the rise in tech.
  • "I'm extending my sincerest congratulations to the winners of the 2022 Moxie Awards Program," saya Maria Christopoulos Katris, CEO, Built In.
  • A judges' panel of celebrated women leaders in tech selected 100 winners, using scorecards with identifying information removed.

Built In Honors Head of Talent Acquisition at Axle in Its 2022 Moxie Awards

Retrieved on: 
Wednesday, April 27, 2022
Moxie, Corporate title, News, CEO, CMO, Data science, Industry, Sex, Courage, Woman, Program, Gender identity, Santa Monica Film Festival & Moxie Awards, Engineering, Management, Axle

NEW YORK, April 27, 2022 /PRNewswire/ -- Built In today announced that Alicia Kortmeyer at Axle was selected as a winner of its 2022 Moxie Awards. The annual awards program recognizes women in tech who have made outsized contributions to their workplaces, communities and the industry as a whole.

Key Points: 
  • NEW YORK, April 27, 2022 /PRNewswire/ -- Built In today announced that Alicia Kortmeyer at Axle was selected as a winner of its 2022 Moxie Awards.
  • "We are beyond proud of Alicia being featured in this group of high-achievers," says Bharath Krishnamoorthy, CEO of Axle.
  • Built In's open call for nominations saw more than 900 entries for 2022.
  • A remote-first company, Axle has been named a Best Place To Work by Built In .

Playmaker Hires New EVP Content, Donald Alexander, to Lead Fast-Growing Snapchat Discover Series

Retrieved on: 
Tuesday, April 26, 2022
TMZ, News, CEO, Athlete, AT&T, Culture, BET, Generation Z, OTT, Playmaker, Executive, AT, Warner Bros., Gen, BBDO, Social media, EVP, CCO, Growth, Moxie, Content creation, AT&T Mobility, 21st Century Fox, YouTube Next Lab and Audience Development Group, Industry, Sport, Cartoon Network, Content, FOX, Entertainment, Snap

Joining Playmaker to take their impressive growth on Snapchat Discover to new heights, Mr. Alexander will work jointly with Chief Content Officer, Devon Harris, as the company's top leader managing their portfolio of 25+ shows on Snapchat Discover which features current sports, culture and celebrity events.

Key Points: 
  • Joining Playmaker to take their impressive growth on Snapchat Discover to new heights, Mr. Alexander will work jointly with Chief Content Officer, Devon Harris, as the company's top leader managing their portfolio of 25+ shows on Snapchat Discover which features current sports, culture and celebrity events.
  • "Playmaker is a formidable leader in the sports content space, especially on Snap, and I'm looking forward to helping them expand their audience and content in areas including entertainment and pop culture," said Donald Alexander, EVP Content at Playmaker.
  • When we asked our trusted advisors & the Snap community, we heard an almost-shocking amount of positive things about Donald.
  • We couldn't be more excited to add him to the Playmaker team," said Brandon Harris, CEO at Playmaker.

Top Tech Integrated Marketing Firm, ARPR, Names New CEO as it Enters 10th Anniversary Year

Retrieved on: 
Thursday, April 7, 2022
Moxie, Binary relation, Marketing, Industry, Technology, Twitter, Possibility, Publicis, Lists of companies, Awareness, Instagram, Public relations, Management

ATLANTA, April 7, 2022 /PRNewswire-PRWeb/ -- As it enters its 10th anniversary year, top tech integrated marketing agency ARPR welcomes Raj Choudhury as its new chief executive officer. With more than 20 years of experience and six prior agency C-suite roles, Raj will take the helm with ARPR's founder Anna Ruth Williams serving as chief strategy officer.

Key Points: 
  • ATLANTA, April 7, 2022 /PRNewswire-PRWeb/ -- As it enters its 10th anniversary year, top tech integrated marketing agency ARPR welcomes Raj Choudhury as its new chief executive officer.
  • "The addition of Raj at the top of our org chart is a natural and seamless progression.
  • For example, in 2016 it became the first tech PR firm to integrate inbound marketing and demand generation into its core capabilities," Choudhury said.
  • ARPR is an integrated marketing agency headquartered in Atlanta with work that reverberates throughout the Americas and Europe.

Reata Pharmaceuticals Completes Rolling Submission of New Drug Application for Omaveloxolone for the Treatment of Patients with Friedreich’s Ataxia

Retrieved on: 
Thursday, March 31, 2022
Biotechnology, FDA, Health, Genetics, Pharmaceutical, Moxie, Therapy, Literature, Forward-looking statement, Extension, Hearing loss, European Commission, Research, Part, Patient, Oxidative stress, Food, Muscle weakness, New Drug Application, Reata Pharmaceuticals, Safety, FA, Omaveloxolone, Diabetes, U.S. Securities and Exchange Commission, Inflammation, Medication, ATP, Nasdaq, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NDA, Cardiomyopathy, Ataxia, Annual report, FDA, Visual impairment, Fatigue, Pharmaceutical industry, NFE2L2, FRIEDREICH'S ATAXIA, OMAVELOXOLONE, REATA

The FDA has granted Fast Track Designation and Orphan Drug Designation to omaveloxolone for the treatment of Friedreichs ataxia.

Key Points: 
  • The FDA has granted Fast Track Designation and Orphan Drug Designation to omaveloxolone for the treatment of Friedreichs ataxia.
  • We look forward to the next steps on the path to making omaveloxolone available as a first-in-class therapy for Friedreichs ataxia, pending approval.
  • The FDA has granted Orphan Drug and Fast Track Designations to omaveloxolone for the treatment of Friedreichs ataxia.
  • The European Commission has granted Orphan Drug Designation in Europe to omaveloxolone for the treatment of Friedreichs ataxia.